- Bioavailability edge: Powder form provides for more thorough and reliable absorption than liquid, enabling superior performance.
- Improved lower variability of the API versus comparator for naloxone as shown in the current study.
- Thought likely to be repeatable to a significant extent with other species of APIs for other therapeutic areas.
- Regulatory runway: Delivery device and API are already approved smoothing the pathway for registration of our innovative take on existing & proven marketed drugs;
- Global trial compliance strategy through EUDAMED.
- Market traction: Broad institutional interest (government, NGOs, pharmacies) due to escalating overdose crises and expanded OTC naloxone approvals.
- Economic tailwinds: Province/state-level bulk purchasing confirms institutional demand.
